Update from the GHMonitorSM observational registry in children treated with recombinant human growth hormone (Saizen®)

Leslie Plotnick, Robert Rapaport, Paul Desrosiers, John S. Fuqua

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Since 2003, the GH MonitorsmSM, an observational registry, has collected data on pediatric subjects treated with Saizen® (recombinant human growth hormone (r-hGH)) in the United States and Canada. This article provides an update on the demographic characteristics of subjects enrolled in the GHMonitorSM Registry. As of August 2007, 1733 subjects were enrolled (68.9% male). The most common primary diagnosis at screening was idiopathic growth hormone deficiency (56.5% of subjects). Of those subjects with available data, mean height standard deviation (SD) score was -2.1±1.0, mean weight SD score was -1.4±1.5, and mean body mass index SD score was -0.1±1.3. Among subjects in whom the presence or absence of other pituitary hormone deficiencies was recorded, 16.1% had multiple pituitary hormone deficiencies. Most patients reported high compliance with therapy (92.6% missed 0-3 doses per month); compliance was similar for all delivery devices (needle Isyringe, cool.click™ or one.click™) used. Two serious adverse events related to Saizen® (hospitalization for placement of right frontal ventriculostomy and right frontal craniotomy for tronscallosal resection of a large recurrent craniopharyngioma and left slipped copitofemoral epiphysis that required pinning of the right hip) were reported in the period from August 2006 to August 2007. This update of the GHMonitorSM Registry continues to provide insight into the characteristics of children treated with this agent and continued evidence of the efficacy and safety of Saizen® in children.

Original languageEnglish (US)
Pages (from-to)278-282
Number of pages5
JournalPediatric Endocrinology Reviews
Issue numberSUPPL. 2
StatePublished - Jan 2009
Externally publishedYes


  • Dose
  • GHMonitor
  • Gonadal steroid hormones
  • Growth hormone
  • Growth hormone deficiency
  • Pituitary hormone deficiency

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Update from the GHMonitorSM observational registry in children treated with recombinant human growth hormone (Saizen®)'. Together they form a unique fingerprint.

Cite this